Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aimed at shoulder pain fails to complete trial

NCT ID NCT05758415

Terminated Symptom relief Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug secukinumab against a placebo in 60 adults with moderate to severe rotator cuff tendinopathy, a painful shoulder condition. The goal was to see if secukinumab could improve symptoms and shoulder function over 24 weeks. However, the trial was terminated early, so its findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
secukinumab
What this could lead to
If successful, secukinumab could offer a new treatment option to reduce pain and improve shoulder function in people with rotator cuff tendinopathy.
What could go wrong
The trial was terminated early with only 60 participants, so results are limited. As a phase 3 study, it may still fail to show benefit or have side effects like infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ROTATOR CUFF TENDINOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

disease of the tendon rotator cuff syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ROTATOR CUFF TENDINOPATHY

Contacts and locations

Locations

  • Conquest Research

    Winter Park, Florida, 32789, United States

  • Horizon Clinical Research

    La Mesa, California, 91942, United States

  • LV Research

    Las Vegas, Nevada, 89119, United States

  • Medvin Clinical Research

    Van Nuys, California, 91405, United States

  • Novartis Investigative Site

    Wuhan, CHN, 430033, China

  • Novartis Investigative Site

    Shijiazhuang, Hebei, 050051, China

  • Novartis Investigative Site

    Wuhan, Hubei, 430022, China

  • Novartis Investigative Site

    Xian, Shanxi, 710004, China

  • Novartis Investigative Site

    Chengdu, Sichuan, 610041, China

  • Novartis Investigative Site

    Shanghai, 200040, China

  • Novartis Investigative Site

    Milan, MI, 20157, Italy

  • Novartis Investigative Site

    Siena, SI, 53100, Italy

  • Novartis Investigative Site

    Krakow, 31-141, Poland

  • Novartis Investigative Site

    Swidnica, 85-100, Poland

  • Novartis Investigative Site

    Torun, 87-100, Poland

  • Novartis Investigative Site

    Warsaw, 00-874, Poland

  • Novartis Investigative Site

    Warsaw, 02-677, Poland

  • Novartis Investigative Site

    Santiago, A Coruna, 15705, Spain

  • Novartis Investigative Site

    Sabadell, Barcelona, 08208, Spain

  • Novartis Investigative Site

    A Coruña, 15006, Spain

  • Novartis Investigative Site

    Madrid, 28034, Spain

  • Novartis Investigative Site

    Valencia, 46024, Spain

  • Novartis Investigative Site

    Bangkok, 10400, Thailand

  • Novartis Investigative Site

    Chiang Mai, 50200, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.